David González de Castro

4.0k citations

59 papers · 2.2k indexed · h-index 28

Cancer Research top 5%
- Cancer Genomics and Diagnostics 20
Oncology top 2%
- Colorectal Cancer Treatments and Studies 20
- Colorectal Cancer Surgical Treatments 5
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 5
Pathology and Forensic Medicine top 5%
- Genetic factors in colorectal cancer 7
- Lymphoma Diagnosis and Treatment 6
Hematology top 5%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 15
- Gastric Cancer Management and Outcomes 7

Co-authors: Paul Workman Paul A. Clarke Bissan Al‐Lazikani Andrew Wotherspoon David Cunningham Ian Chau Manuel Salto‐Tellez Andrés Cervantes
Cited by: Cancer Research Oncology Genetics
Journals: Proceedings of the National Academy of Sciences (1 paper)The Lancet (1 paper)Nature Communications (1 paper)
Partner nations: United Kingdom Spain Sweden

In The Last Decade

David González de Castro

58 papers receiving 2.2k citations

Peers

Countries citing papers authored by David González de Castro

Since Specialization

Citations

This map shows the geographic impact of David González de Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David González de Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David González de Castro more than expected).

Fields of papers citing papers by David González de Castro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David González de Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David González de Castro. The network helps show where David González de Castro may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David González de Castro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David González de Castro Line = papers co-authored together David González de Castro links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials Leukemia ·Mouhamad Khouja,Linmiao Jiang,Karol Pál,Peter J. Stewart,Binaya Regmi,Martin Schwarz,Wolfram Klapper,Stefan Alig,Nikos Darzentas,Hanneke C. Kluin‐Nelemans,Olivier Hermine,Martin Dreyling,David González de Castro,Eva Hoster,Christiane Pott,(unknown)	2024	4
2	Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study Radiation Oncology ·Gerard Walls,Lauren Mc Connell,J. McAleese,P. Murray,Tom Lynch,Kienan I. Savage,Gerard G. Hanna,David González de Castro	2020	16
3	Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial BMC Cancer ·Sarah Brown,Andrew Hall,Hannah Buckley,Louise Flanagan,David González de Castro,Kate Farnell,Laura Moss,Rebecca Gregory,Kate Newbold,Yong Du,Glenn Flux,Jonathan Wadsley	2019	27
4	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma British Journal of Cancer ·Jen Y. Lee,Isaac García-Murillas,Rosalind Cutts,David González de Castro,Lorna Grove,Tara Hurley,Fuqiang Wang,Christopher M. Nutting,K. Newbold,Kevin J. Harrington,Nicholas C. Turner,Shreerang Bhide	2017	103
5	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study Clinical Colorectal Cancer ·Hamzeh Kayhanian,E. Goode,Francesco Sclafani,Joo Ern Ang,Marco Gerlinger,David González de Castro,Scott T.C. Shepherd,Clare Peckitt,Sheela Rao,David Watkins,Ian Chau,David Cunningham,Naureen Starling	2017	46
6	KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial Annals of Oncology ·Francesco Sclafani,Ian Chau,David Cunningham,George Vlachogiannis,Zakaria Eltahir,Andrea Lampis,Chiara Braconi,E. Kalaitzaki,David González de Castro,Andrew Wotherspoon,Jaume Capdevila,B. Glimelius,Andrés Cervantes,Ruwaida Begum,Hazel Lote,Giulia Mentrasti,Jens C. Hahne,Diana Tait,Gina Brown,Nicola Valeri	2016	1
7	Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility Nature Communications ·Kevin Litchfield,Max Levy,Darshna Dudakia,Paula Proszek,Claire Shipley,Sander Basten,Elizabeth Rapley,D. Timothy Bishop,Alison Reid,Robert Huddart,Peter Broderick,David González de Castro,Simon O’Connor,Rachel H. Giles,Richard S. Houlston,Clare Turnbull	2016	29
8	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer Journal of Thoracic Oncology ·Patrizia Viola,Manisha Maurya,James Croud,Jana Gazdová,Nadia Suleman,Eric Lim,Tom Newsom‐Davis,Nick Plowman,Alexandra Rice,M. Angeles Montero,David González de Castro,Sanjay Popat,Andrew G. Nicholson	2016	35
9	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice BMC Research Notes ·Fatma H. Abdelraouf,Adam Sharp,Manisha Maurya,Debbie Mair,Andrew Wotherspoon,Alexandra Léary,David González de Castro,Jaishree Bhosle,Ayatallah Nassef,Taghrid Gaafar,Sanjay Popat,Timothy A. Yap,Mary O’Brien	2015	5
10	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial Annals of Oncology ·Francesco Sclafani,Ian Chau,David Cunningham,Clare Peckitt,Andrea Lampis,Jens C. Hahne,Chiara Braconi,Josep Tabernero,B. Glimelius,Andrés Cervantes,Ruwaida Begum,David González de Castro,Sanna Hulkki Wilson,Zakaria Eltahir,Andrew Wotherspoon,Diana Tait,Gina Brown,J. Oates,Nicola Valeri	2015	19
11	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach PLoS ONE ·Alexandra Pender,Isaac García-Murillas,Sareena Rana,Rosalind Cutts,Gavin Kelly,Kerry Fenwick,Iwanka Kozarewa,David González de Castro,Jaishree Bhosle,Mary O’Brien,Nicholas C. Turner,Sanjay Popat,Julian Downward	2015	48
12	A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material Journal of Thoracic Oncology ·John Le Quesne,Manisha Maurya,Slaveya Yancheva,Mary O’Brien,Sanjay Popat,Andrew Wotherspoon,David González de Castro,Andrew G. Nicholson	2014	36
13	Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients European Journal of Cancer ·Francesco Sclafani,David Cunningham,Josep Tabernero,Bengt Glimelius,Andrés Cervantes,Clare Peckitt,D. Tait,Gina Brown,David González de Castro,Ian Chau	2013	3
14	Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib PLoS ONE ·Fernando López‐Ríos,Bárbara Angulo,Belen Gomez,Debbie Mair,Rebeca Martínez,Esther Conde,Felice Shieh,Jeffrey Vaks,Rachel Langland,H. Jeffrey Lawrence,David González de Castro	2013	38
15	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C) Journal of Clinical Oncology ·Alice Dewdney,David Cunningham,Josep Tabernero,Jaume Capdevila,Bengt Glimelius,Andrés Cervantes,Diana Tait,Gina Brown,Andrew Wotherspoon,David González de Castro,Yu Jo Chua,Rachel Wong,Yolanda Barbáchano,J. Oates,Ian Chau	2012	287
16	A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens British Journal of Cancer ·David González de Castro,Basilio Angulo-Lara,Belen Gomez,Debbie Mair,Roberto Martínez,Ana Suárez‐Gauthier,Felice Shieh,M. Velez,Victoria H. Brophy,H. Jeffrey Lawrence,Fernando López‐Ríos	2012	70
17	Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance Clinical Pharmacology & Therapeutics ·David González de Castro,Paul A. Clarke,Bissan Al‐Lazikani,Paul Workman	2012	172
18	Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors European Journal of Cancer ·Alexandra Léary,David González de Castro,Andrew G. Nicholson,S. Ashley,Andrew Wotherspoon,Mary O’Brien,Sanjay Popat	2011	33
19	REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II. Journal of Clinical Oncology ·Ian Chau,Alicia Okines,David González de Castro,Claire Saffery,Yolanda Barbáchano,Andrew Wotherspoon,L. Puckey,Sanna Hulkki Wilson,Fareeda Y. Coxon,Gary Middleton,D. Ferry,T. Crosby,Srinivasan Madhusudan,Jonathan Wadsley,Justin S. Waters,Marcia Hall,Daniel Swinson,Angus Robinson,Debra L. Smith,David Cunningham	2011	9
20	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL Leukemia & lymphoma ·Alison Morilla,David González de Castro,Ilaria Del Giudice,Nnenna Osuji,Monica Else,Ricardo Morilla,Vasantha Brito Babapulle,Hannah C. Rudenko,Estella Matutes,Claire Dearden,Daniel Catovsky,Gareth J. Morgan	2008	32

About David González de Castro

David González de Castro is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 59 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (20 papers), Colorectal Cancer Treatments and Studies (20 papers), Lung Cancer Treatments and Mutations (15 papers), Gastric Cancer Management and Outcomes (7 papers), Genetic factors in colorectal cancer (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Colorectal Cancer Surgical Treatments (5 papers). The work is most often cited by research in Cancer Research (623 citations), Oncology (1.0k citations) and Genetics (261 citations). David González de Castro has collaborated with scholars based in United Kingdom, Spain and Sweden. Frequent co-authors include Paul Workman, Paul A. Clarke, Bissan Al‐Lazikani, Andrew Wotherspoon, David Cunningham, Ian Chau, Manuel Salto‐Tellez, Andrés Cervantes, Gina Brown and Bengt Glimelius. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact